SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): June 30, 2010
PHARMATHENE,
INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-32587
|
20-2726770
|
||
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
One Park Place, Suite
450, Annapolis, Maryland
|
21401
|
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number including area code: (410) 269-2600
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230
.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
|
Item
1.02
|
Termination
of a Material Definitive Agreement.
|
On June 30, 2010, PharmAthene, Inc.
(the “Company”) and the National Institute of Allergy and Infectious Diseases
(NIAID) entered into a modification to their existing three-year contract
related to development work under the Company’s third-generation anthrax vaccine
program (HHSN272200800049C) (the “3G Contract”). The modification
terminates the 3G Contract as part of a no-cost settlement between the Company
and NIAID.
The Company and NIAID are also parties
to a $15.9 million contract for the advanced development of Valortim® as an
anti-toxin therapeutic to treat inhalation anthrax infection, which contract
remains in full force and effect.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
PHARMATHENE,
INC.
(Registrant)
|
||
|
Date:
July 2, 2010
|
By:
|
/s/
Jordan P. Karp
|
|
Jordan
P. Karp
Senior
Vice President, General Counsel and
Secretary
|
||